Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Schedule an appointment today
Call to Schedule: 1-866-UH4-CARE
Find Clinical Trials & Studies
Visit the Research & Education Institute

VCAR33 in Pts with Relapsed or Refractory Acute Myeloid Leukemia After Transplantation

Back to Search Results
Share
Facebook
X
Pinterest
LinkedIn
Email
Print
I'm Interested!
Please call
1-800-641-2422

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients With Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation

  • Sex at Birth: Any
  • Age: Adult (18 - 64), Older Adult (65+)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase I
  • Conditions Being Studied: Cancer - Leukemia

Study Purpose

This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).

Principal Investigator
Brenda Cooper MD
Department/Division
Cancer (Bone Marrow Transplant)

Locations

UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions
  • UH IRB: STUDY20231361
  • StudyID: VOR1Z23
  • ClinicalTrials.gov: NCT05984199
I'm Interested!
Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422